Updated overall survival and safety profile of durvalumab monotherapy in advanced NSCLC.
暂无分享，去创建一个
J. Nemunaitis | S. Ou | M. Ahn | M. Hellmann | N. Segal | Dong-Wan Kim | Sang-We Kim | G. Jerusalem | P. Schöffski | A. Balmanoukian | D. Jaeger | S. Antonia | J. Brahmer | J. Lutzky | Stephen V. Liu | M. Gutierrez | J. Leach | S. Abdullah | R. Jamal | Y. Gu